PLATFORM
Innovative RNA Platforms for Accelerated Development
Southern RNA provides advanced platforms for mRNA and plasmid DNA development, streamlining the path from research to clinic. Our technology combines synthesis, purification, and analytical workflows, enabling faster iteration and regulatory alignment, helping clients reduce risk and improve efficiency.
CHALLENGES ADDRESSED
Bridging Discovery And Clinical Delivery
RNA therapeutics face unique scientific and operational challenges, including construct optimisation, transcription efficiency, product stability, and regulatory compliance. Our platforms are engineered to address these challenges, providing reliable, scalable, and reproducible solutions that support research, early-phase trials, and GMP-aligned production. This integrated approach reduces variability, minimises risk, and ensures confidence in each stage of development.
ARCHITECTURE & CAPABILITIES
Flexible, Scalable, And Integrated
Our platform combines in vitro transcription, purification, and analytical modules in a fully controlled environment. Capabilities include:
Integrated analytical support for identity, purity, integrity, and stability
Plasmid DNA preparation and quality-assured production
Regulatory-ready documentation and traceability
Scalable purification strategies to support research through early clinical supply
HOW IT WORKS
Streamlined Workflow from Concept to Clinic
Our platform operates as a fully integrated workflow:
01.
Construct design and optimisation for target sequences
02.
High-efficiency RNA or plasmid synthesis
03.
Purification and quality control testing
04.
Analytical verification and batch documentation
05.
Delivery of research-grade, GMP-aligned, or clinical-grade material
QUALITY & COMPLIANCE
Compliance Is Not An Afterthought, It Is Foundational
Quality is central to Southern RNA. Our Quality Management System supports GMP operations and early-phase clinical manufacturing. From raw material qualification to final product release, every step follows documented procedures and risk assessments to ensure consistency and patient safety.
Compliance is embedded in our workflows, not just a final checkpoint. We maintain documentation systems, change management processes, and analytical verification to support regulatory submissions. By aligning quality oversight with execution, we help clients progress confidently from research to clinical supply.
USE CASES
Supporting Research, Development, and Clinical Programmes
Southern RNA’s platform supports RNA development from discovery to early trials. It enables in vitro and in vivo studies, RNA optimisation, and assay development for high-quality data. The platform aids process development and clinical-grade RNA production, supporting early-phase trials. Our technology empowers innovators to accelerate timelines and advance therapeutic candidates.
01
/
04
In vitro and in vivo proof-of-concept studies
Our platform enables researchers to rapidly test RNA constructs in controlled laboratory settings, providing reproducible results and early validation of expression, function, and stability before advancing to more complex models.
02
/
04
Preclinical Development
Preclinical programs benefit from scalable production of research and GMP-aligned grade nucleic acids as they advance toward translational milestones. Southern RNA’s process development and analytical services help ensure consistency, purity, and suitability for later stages of evaluation.
03
/
04
Clinical Supply Enablement
Biopharmaceutical developers preparing for early clinical studies (FIH through Phase I/II) rely on Southern RNA’s GMP-capable workflows to produce clinical-appropriate drug substance. This includes plasmid DNA for viral vector manufacturing and mRNA for vaccines or cell therapies, with quality documentation supporting regulatory needs.
04
/
04
Analytical and Quality Testing
Scientists and quality teams use Southern RNA’s comprehensive analytical platform to characterise nucleic acid products, support method development, and validate stability and release assays. This underpins confidence in product performance and regulatory compliance throughout development.
FAQS
Your Questions Answered
Our FAQ section addresses the most common technical and compliance queries, providing clarity on our capabilities, processes, and quality systems.
Yes, our facilities produce GMP-aligned and clinical-grade mRNA and plasmid DNA suitable for early-phase trials.
We follow GMP-aligned processes, robust documentation, and quality oversight to meet regulatory expectations and support submissions.
We offer flexible production from milligram-scale research material to multi-gram clinical-grade batches.
Yes, our in-house analytical team supports identity, purity, impurity profiling, and stability testing across all projects.
Absolutely. Our team develops reproducible processes for smooth transition from research-scale to GMP-aligned clinical production.